Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
MYGN 
Myriad Genetics Inc (MYGN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: MYGN (2-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
AI Based Fundamental Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Analysis of Past Performance
Type Stock | Historic Profit 10.76% | Avg. Invested days 38 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 807.17M USD | Price to earnings Ratio - | 1Y Target Price 17.77 |
Price to earnings Ratio - | 1Y Target Price 17.77 | ||
Volume (30-day avg) 1095676 | Beta 1.79 | 52 Weeks Range 8.53 - 29.30 | Updated Date 04/1/2025 |
52 Weeks Range 8.53 - 29.30 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.41 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -15.2% | Operating Margin (TTM) -8.22% |
Management Effectiveness
Return on Assets (TTM) -5.06% | Return on Equity (TTM) -17.15% |
Valuation
Trailing PE - | Forward PE 113.64 | Enterprise Value 845072125 | Price to Sales(TTM) 0.96 |
Enterprise Value 845072125 | Price to Sales(TTM) 0.96 | ||
Enterprise Value to Revenue 1.01 | Enterprise Value to EBITDA -23.47 | Shares Outstanding 91309104 | Shares Floating 88896679 |
Shares Outstanding 91309104 | Shares Floating 88896679 | ||
Percent Insiders 2.17 | Percent Institutions 103.99 |
Analyst Ratings
Rating 3.33 | Target Price 21.2 | Buy 3 | Strong Buy 3 |
Buy 3 | Strong Buy 3 | ||
Hold 6 | Sell 2 | Strong Sell 1 | |
Strong Sell 1 |
Upturn AI SWOT
Myriad Genetics Inc
Company Overview
History and Background
Myriad Genetics Inc. was founded in 1991. It became known for BRCA1 and BRCA2 gene testing for breast cancer risk. Over time, it expanded its portfolio to include tests for other cancers, mental health conditions, and autoimmune diseases, facing both scientific advances and competitive pressures.
Core Business Areas
- Oncology: Provides genetic tests to assess cancer risk, guide treatment decisions, and monitor disease progression.
- Mental Health: Offers genetic tests to help personalize treatment for depression and anxiety.
- Pharmacogenomics: Provides testing to predict how patients may respond to specific medications.
Leadership and Structure
Paul J. Diaz serves as President and CEO. The company has a structured organizational chart with executive leadership overseeing various business units and functional departments.
Top Products and Market Share
Key Offerings
- Myriad Preciseu2122 Oncology Solutions: Guides treatment decisions and provides insights into the molecular characteristics of a patient's cancer. Competitors include Foundation Medicine (FMI), Guardant Health (GH), and Exact Sciences (EXAS). Estimated revenue for full year 2024 is $272.5 million according to the 2024 Q3 report.
- GeneSightu00ae Psychotropic Test: A pharmacogenomic test used to help clinicians optimize medication selection for patients with depression, anxiety, and other mental health conditions. Key competitors are Assurex Health (acquired by Myriad), Genomind, and various academic and hospital-based labs. Revenue generated in the 2024 Q3 financial report came in at $47.3 million.
Market Dynamics
Industry Overview
The genetic testing industry is experiencing rapid growth, driven by advancements in genomics, increasing demand for personalized medicine, and growing awareness of the role of genetics in disease. The industry is highly competitive and subject to evolving regulatory landscape.
Positioning
Myriad Genetics Inc. is positioned as a leading provider of genetic testing services, with a focus on oncology, mental health, and pharmacogenomics. The company aims to provide personalized and actionable information to help clinicians and patients make informed healthcare decisions.
Total Addressable Market (TAM)
The global genetic testing market is projected to reach hundreds of billions of dollars. Myriad Genetics is positioned with an extensive test portfolio and has a smaller market share to capture.
Upturn SWOT Analysis
Strengths
- Established brand recognition
- Extensive test portfolio
- Proprietary technologies
- Strong relationships with healthcare providers
- Established reimbursement channels
Weaknesses
- Reliance on a few key products
- Exposure to patent litigation and regulatory challenges
- Historical controversies and negative press
- High debt levels
- Dependence on Medicare
Opportunities
- Expansion into new therapeutic areas
- Development of new genetic tests
- Strategic acquisitions and partnerships
- International expansion
- Increased adoption of personalized medicine
Threats
- Intense competition from other genetic testing companies
- Erosion of patent protection
- Changes in reimbursement policies
- Adverse regulatory actions
- Economic downturn
Competitors and Market Share
Key Competitors
- FMI
- GH
- EXAS
- NVTA
Competitive Landscape
Myriad Genetics Inc. faces strong competition from established players with deep pockets and innovative technologies. The company's advantages include its established brand and extensive test portfolio, but it must continue to innovate and adapt to changing market dynamics to maintain its competitive position.
Major Acquisitions
Counsyl
- Year: 2018
- Acquisition Price (USD millions): 375
- Strategic Rationale: Expanded Myriad's reproductive health testing capabilities, providing comprehensive carrier screening services.
Growth Trajectory and Initiatives
Historical Growth: Myriad Genetics Inc.'s historical growth has been marked by periods of rapid expansion, followed by periods of slower growth and challenges. They've experienced revenue declines in certain business segments.
Future Projections: Future growth projections are dependent on successful commercialization of new products, expansion into new markets, and effective management of competition and regulatory challenges. Analyst estimates vary widely.
Recent Initiatives: Recent initiatives include launching Myriad Preciseu2122 Oncology Solutions, expanding the GeneSightu00ae test's application, and streamlining operations to improve profitability.
Summary
Myriad Genetics is a prominent genetic testing company but faces strong competition in a rapidly evolving market. They have an established brand but need to successfully commercialize new products and control costs to improve financial performance. Success depends on innovation and adapting to industry and regulatory changes.
Similar Companies
EXAS
EXACT Sciences Corporation
EXAS
EXACT Sciences Corporation
GH
Guardant Health Inc
GH
Guardant Health Inc
ILMN
Illumina Inc
ILMN
Illumina Inc
PACB
Pacific Biosciences of California
PACB
Pacific Biosciences of California
Sources and Disclaimers
Data Sources:
- Company Filings (10-K, 10-Q)
- Analyst Reports
- Press Releases
- Industry Reports
Disclaimers:
This analysis is for informational purposes only and does not constitute investment advice. Financial data is based on publicly available information and may not be completely accurate. Market share data is an estimate and may vary depending on the source.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Myriad Genetics Inc
Exchange NASDAQ | Headquaters Salt Lake City, UT, United States | ||
IPO Launch date 1995-10-05 | CEO, President & Director Mr. Paul J. Diaz J.D. | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 2700 | Website https://www.myriad.com |
Full time employees 2700 | Website https://www.myriad.com | ||
Myriad Genetics, Inc., a molecular diagnostic testing and precision medicine company, develops and provides molecular tests in the United States and internationally. The company offers molecular diagnostic tests for oncology, women's health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test to help determine the therapy for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. In addition, the company offers Prolaris Prostate Cancer Prognostic test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor Molecular Profile test, a genomic profiling test; Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus; Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek Early Gender DNA test, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication test, a DNA genotyping test to aid psychotropic drug selection for depression, anxiety, attention-deficit/hyperactivity disorder, and other mental health conditions. It has a license collaboration with Illumina, Inc.; Memorial Sloan Kettering Cancer Center; the University of Texas MD Anderson Cancer Center; the University of Rochester Medical Center; and Flatiron Health, Inc. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.